| Abstrakt: |
A recent study conducted at the University of Pennsylvania has explored the use of liposomes as a drug delivery system to improve the pharmacokinetics, safety, and efficacy of certain medications. The researchers focused on fingolimod, a drug used to treat multiple sclerosis and stroke, which has poor solubility and partitions extensively to plasma proteins and red blood cells. By loading fingolimod into liposomes, the researchers were able to slow its partitioning to red blood cells and plasma proteins, enable intravenous delivery, and prevent toxicity to red blood cells. In animal models, the liposomal formulation showed improved efficacy in treating post-stroke neuroinflammation. This research provides insights into how nanocarriers can be used to optimize the distribution of small molecule drugs for acute illnesses that require rapid intervention. [Extracted from the article] |
